Markets.com Logo
euEnglish
LoginSign Up

Another Monday morning, another positive vaccine update for markets, Cineworld jumps

Nov 23, 2020
5 min read
Table of Contents

    Another Monday morning and another positive vaccine update: AstraZeneca reports its Covid-19 vaccine is 70% effective, helping put a bid under risk assets in early trading on Monday. Astra said this morning that one dosing regimen showed vaccine efficacy of 90% when the AZD1222 vaccine was given as a half dose, followed by a full dose at least one month apart. Another dosing regimen showed 62% efficacy when given as two full doses at least one month apart.

    The combined analysis produced in an average efficacy of 70%. What’s going to be interesting is whether the 90% efficacy with a half dose can be repeated as this would bring it line with the Pfizer and Moderna efficacy rates whilst being significantly easier to rollout at scale.

    Indeed, whilst not as headline-grabbing as a 95% efficacy rate, 70% is by all accounts still very significant and Astra’s vaccine is cheaper, easier to deliver around the world and much easier to produce in large quantities than the Pfizer or Moderna versions, so it will likely play a big role global immunisation. However, the market is not getting the boost as it did from the Pfizer or Moderna updates.

    To a degree that’s because a large amount of market rotation has been priced with November’s gains, and a decent success rate was expected from the Astra/Oxford trials (shares in Astra fell over 1% on the news), but also because in the meantime we have seem soaring case numbers that means the economic recovery will struggle before vaccines take effect.

    European services PMIs for November are weaker due to the lockdowns, whilst manufacturing activity is broadly holding up and the US data due later today probably will just show expansion. But the outlook for 2021 is surely improving the more good vaccine news emerges – the key is how quickly the mass vaccination can occur and how quickly we are ‘back to normal’.

    On that front, there have been reports Britain could give approval to Pfizer-BioNTech vaccine this week, whilst Americans are due to start receiving vaccines next month. Dr Moncef Slaoui, chief scientific adviser for Operation Warp Speed, said the FDA will likely approve the Pfizer/Biontech vaccine by mid-December and inoculations would start immediately thereafter.

    The market is dealing with a familiar theme in terms of the return-to-normal trade. Do bulls bid this up on the reopening trade, or are there greater risks under the bonnet? European markets took a positive view and moved higher, with the FTSE 100 edging up to last week’s highs at 6,400 in early trade. Positive vaccine developments should start to create a much more upbeat picture for the UK market.

    The DAX popped after the manufacturing PMI was stronger than expected at 57.9 and the services survey at 46.2 was much better than France’s rather soft 38.0.

    Cineworld shares leapt 19% after the company bought itself a few more months survival. The company secured a new debt facility of $450m and issued equity warrants representing over 11% of share capital. It also managed to get banks to waive debt covenants until June 2022 and further reduced costs. It’s heavily laden with debt after two leveraged acquisitions but this new facility should act as a bridge to get to a point where it can reopen screens in the UK and US and get the cash flow moving in the right direction again.

    However, the company is working on the assumption that can reopen in May. Under this base case scenario, Cineworld has sufficient headroom for 2021 and beyond. But in the event of a further delay to cinema reopening, whilst it has sufficient liquidity ‘for a number of additional months’, it ‘may require lender support in order to deploy that liquidity’, management said today. Bums on seats by May is dependent entirely on a vaccine – if there is a stock trading on this vaccine roll-out it’s Cineworld.

    WTI crude oil leapt to its highest level since the start of September after Yemen’s Houthis attacked a Saudi Aramco facility in Jeddah. Whilst there is no confirmation of any damage, the reports seem to have put a bid under oil, whilst the positive vaccine news is another support.

    Sterling also rose to its strongest since the start of September amid reports the Brexit deal is 95% agreed. As ever chatter around UK-EU trade talks will drive the price action for sterling crosses.

    Whilst we have many deadlines come and go, several false dawns and lots of disappointment, this really is make-or-break time.

    GBPUSD may be moving in anticipation of a deal – could be a day or two too soon but we shall see. In addition, positive vaccine news would tend to support the pound as the UK economy is more services-driven and more exposed to lockdowns and restrictions on travel, social distancing and consumer confidence.

    GBP performance against USD.


    Risk Warning and Disclaimer: This article represents only the author’s views and is for reference only. It does not constitute investment advice or financial guidance, nor does it represent the stance of the Markets.com platform. Trading Contracts for Difference (CFDs) involves high leverage and significant risks. Before making any trading decisions, we recommend consulting a professional financial advisor to assess your financial situation and risk tolerance. Any trading decisions based on this article are at your own risk.

    Written by
    SHARE

    Markets

    • Palladium - Cash

      chartpng

      --

      0.66%
    • EUR/USD

      chartpng

      --

      0.00%
    • Cotton

      chartpng

      --

      0.86%
    • AUD/USD

      chartpng

      --

      -0.31%
    • Santander

      chartpng

      --

      0.17%
    • Apple.svg

      Apple

      chartpng

      --

      -1.18%
    • easyJet

      chartpng

      --

      0.34%
    • VIXX

      chartpng

      --

      -0.26%
    • Silver

      chartpng

      --

      -0.54%
    Table of Contents

      Related Articles

      Trump Admin Leverages Fed Renovation for Powell Ouster Amid Rate Dispute

      The Federal Reserve's independence faces challenges as the Trump administration uses costly building renovations as leverage amid disagreements over interest rates. The article analyzes the potential implications for monetary policy.

      Sophia Claire|about 2 hours ago

      Pound Sterling Outlook: Interest Rates and Economic Indicators in Focus

      The pound sterling is heading for its longest losing streak in two years as expectations of Bank of England interest rate cuts and weak economic data weigh on the currency. This article analyzes the factors affecting the British currency.

      Emma Rose|about 2 hours ago

      Trump's Tariff Threat Looms: Will It Trigger EU Recession and Force ECB Rate Cuts?

      This article explores how Trump's tariff threats against the EU could lead to a deeper economic slowdown and push the ECB to cut interest rates. It also analyzes the perspectives of major financial institutions.

      Sophia Claire|about 6 hours ago
      Markets.com Logo
      google playapp storeweb tradertradingView

      Contact Us

      support@markets.com+12845680155

      Markets

      • Forex
      • Shares
      • Commodities
      • Indices
      • Crypto
      • ETFs
      • Bonds

      Trading

      • Trading Tools
      • Platform
      • Web Platform
      • App
      • TradingView
      • MT4
      • MT5
      • CFD Trading
      • CFD Asset List
      • Trading Info
      • Trading Conditions
      • Trading Hours
      • Trading Calculators
      • Economic Calendar

      Learn

      • News
      • Trading Basics
      • Glossary
      • Webinars
      • Traders' Clinic
      • Education Centre

      About

      • Why markets.com
      • Global Offering
      • Our Group
      • Careers
      • FAQs
      • Legal Pack
      • Safety Online
      • Complaints
      • Contact Support
      • Help Centre
      • Sitemap
      • Cookie Disclosure
      • Regulation
      • Awards and Media

      Promo

      • Gold Festival
      • Crypto Trading
      • marketsClub
      • Welcome Bonus
      • Loyal Bonus
      • Referral Bonus

      Partnership

      • Affiliation
      • IB

      Follow us on

      • Facebook
      • Instagram
      • Twitter
      • Youtube
      • Linkedin
      • Threads
      • Tiktok

      Listed on

      • 2023 Best Trading Platform Middle East - International Business Magazine
      • 2023 Best Trading Conditions Broker - Forexing.com
      • 2023 Most Trusted Forex Broker - Forexing.com
      • 2023 Most Transparent Broker - AllForexBonus.com
      • 2024 Best Broker for Beginners, United Kingdom - Global Brands Magazine
      • 2024 Best MT4 & MT5 Trading Platform Europe - Brands Review Magazine
      • 2024 Top Research and Education Resources Asia - Global Business and Finance Magazine
      • 2024 Leading CFD Broker Africa - Brands Review Magazine
      • 2024 Best Broker For Beginners LATAM - Global Business and Finance Magazine
      • 2024 Best Mobile Trading App MENA - Brands Review Magazine
      • 2024 Best Outstanding Value Brokerage MENA - Global Business and Finance Magazine
      • 2024 Best Broker for Customer Service MENA - Global Business and Finance Magazine
      LegalLegal PackCookie DisclosureSafety Online

      Payment
      Methods

      mastercardvisanetellerskrillwire transferzotapay
      The markets.com/za/ site is operated by Markets South Africa (Pty) Ltd which is a regulated by the FSCA under license no. 46860 and licensed to operate as an Over The Counter Derivatives Provider (ODP) in terms of the Financial Markets Act no.19 of 2012. Markets South Africa (Pty) Ltd is located at BOUNDARY PLACE 18 RIVONIA ROAD, ILLOVO SANDTON, JOHANNESBURG, GAUTENG, 2196, South Africa. 

      High Risk Investment Warning: Trading Foreign Exchange (Forex) and Contracts For Difference (CFDs) is highly speculative, carries a high level of risk and is not appropriate for every investor. You may sustain a loss of some or all of your invested capital, therefore, you should not speculate with capital that you cannot afford to lose. You should be aware of all the risks associated with trading on margin. Please read the full  Risk Disclosure Statement which gives you a more detailed explanation of the risks involved.

      For privacy and data protection related complaints please contact us at privacy@markets.com. Please read our PRIVACY POLICY STATEMENT for more information on handling of personal data.

      Markets.com operates through the following subsidiaries:

      Safecap Investments Limited, which is regulated by the Cyprus Securities and Exchange Commission (“CySEC”) under license no. 092/08. Safecap is incorporated in the Republic of Cyprus under company number ΗΕ186196.

      Finalto International Limited is registered  in the Saint Vincent and The Grenadines (“SVG”) under the revised Laws of Saint Vincent and The Grenadines 2009, with registration number  27030 BC 2023.

      Close
      Close

      set cookie

      set cookie

      We use cookies to do things like offer live chat support and show you content we think you’ll be interested in. If you’re happy with the use of cookies by markets.com, click accept.